One of Merck’s next-generation pneumococcal vaccines has sailed through a mid-stage trial and is being readied for a phase 3 study next month. V116—one of three pneumococcal vaccines in Merck’s ...

Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114. Merck announced positive topline results ...

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...

PNEUMOVAX 23 contains a mixture of inactive parts from 23 of the most common types of pneumococcal bacteria. PNEUMOVAX 23 is a vaccine given to help prevent infections caused by certain types of germs ...